PLIANT THERAPEUTICS, INC. (PLRX) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-07-13

PLIANT THERAPEUTICS, INC. (PLRX) has filed 12 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-13. 4 Form 8-K material event filings were reported by PLRX in the last 90 days. InsiderAlpha tracks every PLRX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About PLIANT THERAPEUTICS, INC. (PLRX)

SEC CIK	0001746473

90-Day SEC Filing Activity

Form 4 filings (90d)	12
Form 8-K filings (90d)	4
Latest Form 4 filing	2026-07-13

Recent PLRX Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-01-20	Cheung Lily	Chief Human Resource Officer	S — Open-market sale [10b5-1]	7.5K	$1.28	$10K	SEC
2026-01-20	Coulie Bernard	President and CEO	S — Open-market sale [10b5-1]	89.4K	$1.28	$114K	SEC
2026-01-20	Kuo Minnie	Chief Operating Officer	S — Open-market sale [10b5-1]	6.9K	$1.28	$9K	SEC
2026-01-20	Cummings Keith Lamont	Chief Financial Officer	S — Open-market sale [10b5-1]	24.0K	$1.28	$31K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for PLIANT THERAPEUTICS, INC. (PLRX). Updated in real time as new filings are submitted to the SEC.

Most-Active PLRX Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Coulie Bernard	14	—
Cummings Keith Lamont	14	—
Cheung Lily	6	—
Kuo Minnie	6	—
Huh Hoyoung	1	—

Recent PLRX Form 8-K Material Events

2026-07-13 — Item 5.02 [SEC]
2026-06-11 — Item 5.07 [SEC]
2026-05-11 — Item 2.02, 9.01 [SEC]
2026-04-17 — Item 5.02 · Leadership · neutral [SEC]
Two board directors at Pliant Therapeutics announced their retirements effective at the 2026 Annual Meeting of Stockholders. David E.I. Pyott (Class I director, Audit Committee and Nominating/Corporate Governance Committee member) and Katharine Knobil, M.D. (Class II director, Re
2026-03-30 — Item 8.01 · Financing · neutral [SEC]
Pliant Therapeutics terminated its existing 2021 at-the-market (ATM) sales agreement with Cantor Fitzgerald and entered into a new $50 million ATM offering program with Leerink Partners effective March 27, 2026. The company did not sell any shares under the prior agreement and fa

Recent Insider Filings

2026-07-13 — Iannone Robert (Director)
2026-07-13 — Borellini Flavia (Director)
2026-06-12 — CROWELL GAYLE A (Director)
2026-06-12 — MCCOURT Thomas A (Director)
2026-06-12 — Krognes Steve E. (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in PLRX insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

PLRX Insider Trading — FAQ

What is the latest insider trade for PLRX?: PLIANT THERAPEUTICS, INC. (PLRX) had 12 insider filings in the last 90 days, with the most recent on 2026-07-13. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying PLRX stock?: 0 insider purchases of PLRX were filed in the last 90 days.
How many insiders are selling PLRX stock?: 0 insider sales of PLRX were filed in the last 90 days.
Where can I see PLRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every PLRX SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live PLRX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.